YOLFTbeta
Protara Therapeutics Inc

Protara Therapeutics Inc

TARA · NASDAQ · Healthcare / Biotechnology

2.53USD+0.09 (+3.69%)

Price History

Full chart

Market Stats

Previous Close2.44
Open2.49
Day Range2.37 – 2.58
52-Week Range3.19 – 7.82
Volume728.22K
Market Cap193.83M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.36
Dividend Yield0.00%
Beta1.49
50-Day Avg3.90
200-Day Avg4.93

About

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jesse Shefferman
  • Employees46
  • Headquarters345 Park Avenue South, New York, NY, United States, 10010, USA
  • Websitehttps://www.protaratx.com

Leadership

  • Mr. Jesse SheffermanCo-founder, CEO, President & Director · b. 1972
  • Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D.Co-Founder, Chief R&D Officer · b. 1981
  • Mr. Patrick Fabbio M.B.A.Chief Financial Officer · b. 1968
  • Ms. Hannah FryVP, Principal Accounting Officer & Controller · b. 1991
  • Ms. Justine O'MalleySenior Vice President of Investor Relations & Corporate Affairs
  • Ms. Mary J. Grendell J.D.General Counsel & Corporate Secretary
  • Dr. Shane Williams Ph.D.Chief People Officer
  • Mr. William ConklingChief Commercial Officer · b. 1971
  • Carla Beckham M.D., Ph.D.Lead Medical Director, Head of Clinical Development of TARA-002 in NMIBC & Board-Certified Urologist
  • Dr. Neal D. Shore F.A.C.S., M.D.Medical Director of START Carolinas/ Carolina Urologic Research Center

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--2.95M----0000000
Cost of Revenue57.00K27.00K-57.00K123.00K148.00K115.00K16.00K196.00K1.17M247.00K341.00K332.00K362.00K
Gross Profit-57.00K-27.00K2.95M-57.00K-123.00K-148.00K-115.00K-16.00K-196.00K-1.17M-247.00K-341.00K-332.00K-362.00K
Gross Margin--100.00%-----------
Operating Expense7.94M7.09M10.53M20.81M28.58M30.21M25.96M15.24M34.25M46.32M66.81M43.27M48.82M64.19M
Operating Income-8.00M-7.12M-7.58M-20.87M-28.70M-30.36M-26.08M-15.25M-34.44M-47.49M-67.06M-43.61M-49.15M-64.55M
Operating Margin---257.12%-----------
EBITDA-7.91M-7.02M-2.46M-21.32M-28.40M-29.82M-20.61M-7.81M-33.78M-45.40M-64.57M-40.08M-44.26M-57.08M
EBITDA Margin---83.28%-----------
Net Income-7.97M-7.91M-3.34M-21.38M-28.53M-29.96M-25.44M-14.99M-33.98M-47.25M-65.95M-40.42M-44.60M-57.44M
Net Income Margin---113.36%-----------
R&D5.91M3.99M6.43M12.38M18.87M21.69M15.51M6.44M11.88M21.09M16.81M24.79M31.70M42.63M
R&D as % of Total Revenue--218.18%-----------
Interest Expense-861.00K857.00K144.00K193.00K259.00K0034.00K1.74M1.14M-4.17M-
Interest Expense % of Total Revenue--29.07%-----------

Balance Sheet

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets7.78M5.66M84.80M67.54M43.52M43.98M23.52M6.97M203.16M172.60M113.29M78.95M181.45M209.47M
Total Liabilities4.15M9.77M2.34M4.13M5.08M9.24M3.08M583.00K3.91M10.68M11.21M10.63M14.32M13.06M
Total Equity3.63M-4.11M82.46M63.41M38.44M34.74M20.44M6.39M199.24M161.91M102.08M68.32M167.13M196.41M
Cash2.41M2.83M68.84M40.03M36.39M21.17M19.37M6.18M168.60M35.72M24.13M39.59M162.80M49.66M
Total Debt-5.06M---20.00K--1.09M7.24M6.38M5.47M4.48M3.36M
Net Debt-2.41M2.23M-68.84M-40.03M-36.39M-21.15M-19.37M-6.18M-167.51M-28.48M-17.74M-34.12M-158.31M-46.30M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-8.23M-6.70M-9.99M-17.57M-23.69M-22.35M-23.23M-15.65M-23.41M-34.50M-26.46M-37.56M-35.81M-56.37M
Investing Cash Flow7.38M2.73M-12.48M-11.33M19.92M-16.10M18.43M2.48M2.83M-98.19M14.95M53.11M19.16M-139.49M
Financing Cash Flow-9.00K4.36M88.52M163.00K208.00K23.05M2.98M500.00K189.40M-228.00K-90.00K-91.00K139.87M82.72M
Capital Expenditure67.00K10.00K51.00K198.00K271.00K35.00K119.00K16.00K884.00K596.00K120.00K45.00K63.00K94.00K
Free Cash Flow-8.30M-6.71M-10.04M-17.76M-23.96M-22.39M-23.35M-15.66M-24.29M-35.10M-26.58M-37.60M-35.87M-56.46M
FCF to OCF100.81%100.15%100.51%101.13%101.14%100.16%100.51%100.10%103.78%101.73%100.45%100.12%100.18%100.17%

Earnings

Report DateNov 25, 2014Mar 20, 2015May 13, 2015Aug 13, 2015Nov 12, 2015Mar 14, 2016May 9, 2016Aug 8, 2016Nov 7, 2016Mar 16, 2017May 10, 2017Aug 7, 2017Nov 7, 2017Mar 14, 2018May 9, 2018Aug 7, 2018Nov 7, 2018Mar 13, 2019May 8, 2019Aug 7, 2019Oct 31, 2019Mar 20, 2020May 13, 2020Jul 31, 2020Nov 12, 2020Mar 11, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Mar 9, 2022May 5, 2022Aug 9, 2022Nov 3, 2022Mar 8, 2023May 4, 2023Aug 3, 2023Nov 3, 2023Mar 13, 2024May 2, 2024Aug 6, 2024Nov 12, 2024Mar 11, 2025May 8, 2025Aug 11, 2025Nov 10, 2025Mar 10, 2026May 13, 2026Aug 11, 2026Nov 9, 2026
EPS Estimate-12.60-10.53-12.30-11.87-13.20-13.70-16.32-17.04-18.80-18.30-16.70-17.20-15.53-16.80-13.84-14.20-12.00-10.20-9.00-6.80-3.60-0.71-0.41-0.83-0.62-0.54-0.63-0.96-0.96-0.94-0.77-0.78-0.70-0.75-0.87-0.94-0.98-0.92-0.92-0.74-0.52-0.56-0.48-0.41-0.38-0.31-0.37-0.33-0.37
EPS Actual-1241.20-9.44-11.20-12.40-13.20-15.60-16.00-19.20-17.20-16.80-15.60-13.20-28.00-12.40-13.60-11.20-10.00-10.80-13.60-10.80-3.20-2.55-1.81-1.22-1.26-0.44-1.20-1.14-0.96-0.91-0.96-0.80-0.68-1.55-0.80-1.00-0.87-0.90-0.97-0.45-0.50-0.43-0.29-0.35-0.31-0.38-0.31-0.36-
Surprise-9750.79%10.35%8.94%-4.46%0.00%-13.87%1.96%-12.68%8.51%8.20%6.59%23.26%-80.30%26.19%1.73%21.13%16.67%-5.88%-51.11%-58.82%11.11%-259.15%-341.46%-46.99%-103.23%18.52%-90.48%-18.75%0.00%3.19%-24.68%-2.56%2.86%-106.67%8.05%-6.38%11.22%2.17%-5.43%39.19%3.85%23.89%39.58%14.63%18.42%-21.79%16.22%-9.09%-
TimingPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap193.83M
Enterprise Value69.45M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book1.30
EPS-1.36
Book Value2.73
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-76.45M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-45.80%
Return on Assets-28.82%
Shares Outstanding59.10M
Shares Float54.88M
Beta1.49
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 7 analystsTarget 25.71
  • Strong Buy
    5
  • Buy
    2

Ownership Breakdown

Institutions
78.39%
Insiders
2.30%
Retail / Other
19.31%

Top Institutional Holders

  • HHG PLC
    5.21M8.81%
  • BlackRock Inc
    3.39M5.74%
  • Millennium Management LLC
    3.10M5.25%
  • Velan Capital Investment Management LP
    2.84M4.81%
  • Blackstone Inc
    2.27M3.83%
  • Vanguard Capital Management, LLC
    2.12M3.59%
  • Sio Capital Management, LLC
    1.92M3.25%
  • Integral Health Asset Management, LLC
    1.50M2.54%
  • UBS Group AG
    1.40M2.37%
  • 5AM Venture Management, LLC
    1.37M2.32%
  • Citadel Advisors Llc
    1.23M2.09%
  • Geode Capital Management, LLC
    1.18M1.99%
  • Point72 Asset Management, L.P.
    1.15M1.95%
  • State Street Corp
    1.01M1.70%
  • Baker Bros Advisors LP
    971.61K1.64%
  • ADAR1 Capital Management LLC
    940.51K1.59%
  • Bank of America Corp
    925.92K1.57%
  • J. Goldman & Co LP
    856.25K1.45%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.66M2.81%
  • iShares Russell 2000 ETF
    1.34M2.27%

Stock Splits

  • Jan 10, 20201:40